- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the mRNA Vaccines & Therapeutics market will register a 9.0% CAGR in terms of revenue, the global market size will reach $ 1625.8 million by 2025, from $ 1150.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in mRNA Vaccines & Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccines & Therapeutics market by type, application, key manufacturers and key regions and countries.
This study considers the mRNA Vaccines & Therapeutics value and volume generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Standardization Of Cancer Treatment MRNA Vaccine
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Infectious Disease
Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Moderna Therapeutics
Tiba Biotechnology
CureVac
BioNTech
Sangamo Therapeutics
Translate Bio
eTheRNA
Argos Therapeutics
Ethris
In-Cell-Art
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global mRNA Vaccines & Therapeutics consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of mRNA Vaccines & Therapeutics market by identifying its various subsegments.
Focuses on the key global mRNA Vaccines & Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the mRNA Vaccines & Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of mRNA Vaccines & Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global mRNA Vaccines & Therapeutics Consumption 2015-2025
2.1.2 mRNA Vaccines & Therapeutics Consumption CAGR by Region
2.2 mRNA Vaccines & Therapeutics Segment by Type
2.2.1 Standardization Of Cancer Treatment MRNA Vaccine
2.2.2 Individualized Cancer Treatment MRNA Vaccine
2.2.3 Infectious Disease Treatment MRNA Vaccine
2.2.4 Infection Prevention MRNA Vaccine
2.3 mRNA Vaccines & Therapeutics Consumption by Type
2.3.1 Global mRNA Vaccines & Therapeutics Consumption Market Share by Type (2015-2020)
2.3.2 Global mRNA Vaccines & Therapeutics Revenue and Market Share by Type (2015-2020)
2.3.3 Global mRNA Vaccines & Therapeutics Sale Price by Type (2015-2020)
2.4 mRNA Vaccines & Therapeutics Segment by Application
2.4.1 Infectious Disease
2.4.2 Cancer
2.4.3 Other
2.5 mRNA Vaccines & Therapeutics Consumption by Application
2.5.1 Global mRNA Vaccines & Therapeutics Consumption Market Share by Type (2015-2020)
2.5.2 Global mRNA Vaccines & Therapeutics Value and Market Share by Type (2015-2020)
2.5.3 Global mRNA Vaccines & Therapeutics Sale Price by Type (2015-2020)
3 Global mRNA Vaccines & Therapeutics by Company
3.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Company
3.1.1 Global mRNA Vaccines & Therapeutics Sales by Company (2018-2020)
3.1.2 Global mRNA Vaccines & Therapeutics Sales Market Share by Company (2018-2020)
3.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Company
3.2.1 Global mRNA Vaccines & Therapeutics Revenue by Company (2018-2020)
3.2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Company (2018-2020)
3.3 Global mRNA Vaccines & Therapeutics Sale Price by Company
3.4 Global mRNA Vaccines & Therapeutics Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global mRNA Vaccines & Therapeutics Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players mRNA Vaccines & Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 mRNA Vaccines & Therapeutics by Regions
4.1 mRNA Vaccines & Therapeutics by Regions
4.2 Americas mRNA Vaccines & Therapeutics Consumption Growth
4.3 APAC mRNA Vaccines & Therapeutics Consumption Growth
4.4 Europe mRNA Vaccines & Therapeutics Consumption Growth
4.5 Middle East & Africa mRNA Vaccines & Therapeutics Consumption Growth
5 Americas
5.1 Americas mRNA Vaccines & Therapeutics Consumption by Countries
5.1.1 Americas mRNA Vaccines & Therapeutics Consumption by Countries (2015-2020)
5.1.2 Americas mRNA Vaccines & Therapeutics Value by Countries (2015-2020)
5.2 Americas mRNA Vaccines & Therapeutics Consumption by Type
5.3 Americas mRNA Vaccines & Therapeutics Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC mRNA Vaccines & Therapeutics Consumption by Regions
6.1.1 APAC mRNA Vaccines & Therapeutics Consumption by Regions (2015-2020)
6.1.2 APAC mRNA Vaccines & Therapeutics Value by Regions (2015-2020)
6.2 APAC mRNA Vaccines & Therapeutics Consumption by Type
6.3 APAC mRNA Vaccines & Therapeutics Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe mRNA Vaccines & Therapeutics by Countries
7.1.1 Europe mRNA Vaccines & Therapeutics Consumption by Countries (2015-2020)
7.1.2 Europe mRNA Vaccines & Therapeutics Value by Countries (2015-2020)
7.2 Europe mRNA Vaccines & Therapeutics Consumption by Type
7.3 Europe mRNA Vaccines & Therapeutics Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa mRNA Vaccines & Therapeutics by Countries
8.1.1 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa mRNA Vaccines & Therapeutics Value by Countries (2015-2020)
8.2 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Type
8.3 Middle East & Africa mRNA Vaccines & Therapeutics Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 mRNA Vaccines & Therapeutics Distributors
10.3 mRNA Vaccines & Therapeutics Customer
11 Global mRNA Vaccines & Therapeutics Market Forecast
11.1 Global mRNA Vaccines & Therapeutics Consumption Forecast (2021-2025)
11.2 Global mRNA Vaccines & Therapeutics Forecast by Regions
11.2.1 Global mRNA Vaccines & Therapeutics Forecast by Regions (2021-2025)
11.2.2 Global mRNA Vaccines & Therapeutics Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global mRNA Vaccines & Therapeutics Forecast by Type
11.8 Global mRNA Vaccines & Therapeutics Forecast by Application
12 Key Players Analysis
12.1 Moderna Therapeutics
12.1.1 Company Information
12.1.2 mRNA Vaccines & Therapeutics Product Offered
12.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Moderna Therapeutics Latest Developments
12.2 Tiba Biotechnology
12.2.1 Company Information
12.2.2 mRNA Vaccines & Therapeutics Product Offered
12.2.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Tiba Biotechnology Latest Developments
12.3 CureVac
12.3.1 Company Information
12.3.2 mRNA Vaccines & Therapeutics Product Offered
12.3.3 CureVac mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 CureVac Latest Developments
12.4 BioNTech
12.4.1 Company Information
12.4.2 mRNA Vaccines & Therapeutics Product Offered
12.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 BioNTech Latest Developments
12.5 Sangamo Therapeutics
12.5.1 Company Information
12.5.2 mRNA Vaccines & Therapeutics Product Offered
12.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Sangamo Therapeutics Latest Developments
12.6 Translate Bio
12.6.1 Company Information
12.6.2 mRNA Vaccines & Therapeutics Product Offered
12.6.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Translate Bio Latest Developments
12.7 eTheRNA
12.7.1 Company Information
12.7.2 mRNA Vaccines & Therapeutics Product Offered
12.7.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 eTheRNA Latest Developments
12.8 Argos Therapeutics
12.8.1 Company Information
12.8.2 mRNA Vaccines & Therapeutics Product Offered
12.8.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Argos Therapeutics Latest Developments
12.9 Ethris
12.9.1 Company Information
12.9.2 mRNA Vaccines & Therapeutics Product Offered
12.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Ethris Latest Developments
12.10 In-Cell-Art
12.10.1 Company Information
12.10.2 mRNA Vaccines & Therapeutics Product Offered
12.10.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 In-Cell-Art Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. mRNA Vaccines & Therapeutics Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
